156 related articles for article (PubMed ID: 7937748)
21. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody.
Angal S; King DJ; Bodmer MW; Turner A; Lawson AD; Roberts G; Pedley B; Adair JR
Mol Immunol; 1993 Jan; 30(1):105-8. PubMed ID: 8417368
[TBL] [Abstract][Full Text] [Related]
22. Intrachain disulfide bond in the core hinge region of human IgG4.
Bloom JW; Madanat MS; Marriott D; Wong T; Chan SY
Protein Sci; 1997 Feb; 6(2):407-15. PubMed ID: 9041643
[TBL] [Abstract][Full Text] [Related]
23. A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells.
Michaelsen TE; Thommesen JE; Ihle O; Gregers TF; Sandin RH; Brekke OH; Sandlie I
Eur J Immunol; 2006 Jan; 36(1):129-38. PubMed ID: 16323243
[TBL] [Abstract][Full Text] [Related]
24. Human IgG3 is decreased and IgG1, IgG2 and IgG4 are unchanged in molecular size by mild reduction and reoxidation without any major change in effector functions.
Michaelsen TE; Naess LM; Aase A
Mol Immunol; 1993 Jan; 30(1):35-45. PubMed ID: 8417373
[TBL] [Abstract][Full Text] [Related]
25. Sequence of a rat immunoglobulin gamma 2c heavy chain constant region cDNA: extensive homology to mouse gamma 3.
Brüggemann M; Delmastro-Galfrè P; Waldmann H; Calabi F
Eur J Immunol; 1988 Feb; 18(2):317-9. PubMed ID: 3127222
[TBL] [Abstract][Full Text] [Related]
26. Transferrin-antibody fusion proteins are effective in brain targeting.
Shin SU; Friden P; Moran M; Olson T; Kang YS; Pardridge WM; Morrison SL
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2820-4. PubMed ID: 7708731
[TBL] [Abstract][Full Text] [Related]
27. Modulation of the effector functions of a human IgG1 through engineering of its hinge region.
Dall'Acqua WF; Cook KE; Damschroder MM; Woods RM; Wu H
J Immunol; 2006 Jul; 177(2):1129-38. PubMed ID: 16818770
[TBL] [Abstract][Full Text] [Related]
28. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
29. Different glycosylation pattern of human IgG1 and IgG3 antibodies isolated from transiently as well as permanently transfected cell lines.
Vestrheim AC; Moen A; Egge-Jacobsen W; Bratlie DB; Michaelsen TE
Scand J Immunol; 2013 May; 77(5):419-28. PubMed ID: 23488770
[TBL] [Abstract][Full Text] [Related]
30. Structural difference in the complement activation site of human IgG1 and IgG3.
Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O
Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198
[TBL] [Abstract][Full Text] [Related]
31. A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha.
Brüggemann M; Teale C; Clark M; Bindon C; Waldmann H
J Immunol; 1989 May; 142(9):3145-50. PubMed ID: 2496159
[TBL] [Abstract][Full Text] [Related]
32. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.
Dangl JL; Wensel TG; Morrison SL; Stryer L; Herzenberg LA; Oi VT
EMBO J; 1988 Jul; 7(7):1989-94. PubMed ID: 3138110
[TBL] [Abstract][Full Text] [Related]
33. A genetically engineered human IgG with limited flexibility fully initiates cytolysis via complement.
Shopes B
Mol Immunol; 1993 Apr; 30(6):603-9. PubMed ID: 8487779
[TBL] [Abstract][Full Text] [Related]
34. Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions.
Reitan SK; Hannestad K
Proc Natl Acad Sci U S A; 2002 May; 99(11):7588-93. PubMed ID: 12032327
[TBL] [Abstract][Full Text] [Related]
35. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
36. Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity.
Giuntini S; Granoff DM; Beernink PT; Ihle O; Bratlie D; Michaelsen TE
Clin Vaccine Immunol; 2016 Aug; 23(8):698-706. PubMed ID: 27307451
[TBL] [Abstract][Full Text] [Related]
37. Aglycosylated chimaeric human IgG3 can trigger the human phagocyte respiratory burst.
Pound JD; Lund J; Jefferis R
Mol Immunol; 1993 Feb; 30(3):233-41. PubMed ID: 8381917
[TBL] [Abstract][Full Text] [Related]
38. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Immunol Methods; 2005 Nov; 306(1-2):93-103. PubMed ID: 16236307
[TBL] [Abstract][Full Text] [Related]
39. Chimerization of antitumor antibodies via homologous recombination conversion vectors.
Yarnold S; Fell HP
Cancer Res; 1994 Jan; 54(2):506-12. PubMed ID: 7506124
[TBL] [Abstract][Full Text] [Related]
40. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
